

Imugene Announces Presentations on Lead PD-1 and HER-2 Cancer Vaccines at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia, 4 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The presentations will be presented by Dr Saab, the co-inventor of the KEY-Vaxx and B-Vaxx cancer vaccines with Professor Pravin Kaumaya, and member of the Company's Scientific Advisory Board, at the AACR Annual Meeting in Atlanta, Georgia scheduled for March 29 to April 3, 2019.

The abstract presentations are entitled 'Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line' and 'A Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors.'

The abstracts were authored by Dr Saab from the Mayo Clinic Cancer Center in Phoenix, AZ and researchers, including Prof. Kaumaya at the Ohio State University, Columbus, OH, UCLA, Los Angeles, CA and Emory University, Atlanta, GA.

Imugene's KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumors such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.

KEY-Vaxx when combined with B-Vaxx has shown great potential in preclinical studies, showing robust PD-1 and HER-2 antibody responses in all vaccinated mice indicating that the combined vaccination is effective in reducing tumor growth in a Balb/c syngeneic model of colon carcinoma versus either the PD-1 vaccine alone or more importantly the positive control gold standard that is anti-mouse PD-1 monoclonal antibody. The vaccine combination was found to be safe and did not

appear to exhibit toxicity or autoimmunity. Imugene is working to evaluate KEY-Vaxx and its potential efficacy in a range of cancers.

The Phase I B-Vaxx trial studied the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides may help the body build an effective immune response to kill tumor cells.

The open-label, dose escalation study evaluated B-Vaxx in patients with solid tumors that over express the HER-2/neu receptor. B-Vaxx has been shown to stimulate a potent polyclonal antibody response to HER-2/neu , a well established and validated cancer target.

B-Vaxx is a proprietary B-cell peptide cancer vaccine being developed by Imugene and targeting multiple oncology indications. A Phase 2 study evaluating the activity of B-Vaxx in patients over expressing HER-2/neu is being conducted at renowned clinical institutions in the US.

The abstract describes data from preclinical studies and a Phase I study conducted by the research team at Ohio State University Comprehensive Cancer Centre led by Professor Kaumaya with B-Vaxx for the treatment of solid tumors.

The content of the presentations are embargoed until the start of the conference and will be made available online after the start of the meeting and on the Imugene website.

An additional abstract detailing research from Imugene's PD-1 Mimotope (Medical University of Vienna) program has also been accepted for poster presentation.

For further information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](#)

Like us on Facebook [@Imugene](#)

Connect with us on LinkedIn [@Imugene Limited](#)

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.